ArticleQuantitative imaging in medicine and surgery2026
Amide proton transfer-weighted magnetic resonance imaging for the diagnosis of triple-negative breast cancer: a comparative study with diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging.
Article in Quantitative imaging in medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Amide proton transfer-weighted (APTw) imaging is an emerging molecular magnetic resonance imaging (MRI) technique that enables the noninvasive quantification of endogenous mobile proteins and peptides. This study aimed to preliminarily evaluate the diagnostic performance of multipool chemical exchange saturation transfer (CEST)-derived parameters for differentiating benign from malignant breast lesions and identifying triple-negative breast cancer (TNBC) and to compare this modality with diffusion-weighted imaging (DWI) and dynamic contrast-enhanced MRI (DCE-MRI). Methods: This prospective single-center study included 148 patients with breast lesions who underwent 3 T APTw, DWI, and DCE-MRI examinations. Pathological results were used to classify lesions as benign or malignant and to determine molecular subtypes based on immunohistochemistry. Twelve CEST-derived metabolic parameters, the apparent diffusion coefficient (ADC), and DCE-MRI parameters [volume transfer constant (Ktrans), rate constant (Kep), and extracellular extravascular volume fraction (Ve)] were compared between benign and malignant lesions, as well as between TNBC and non-TNBC subtypes. Diagnostic performance was assessed via the receiver operating characteristic (ROC) analysis and area under the curve (AUC) calculations. Results: A total of 148 breast lesions were included in the analysis, among which 43 were benign and 105 malignant [luminal A: n=26; luminal B: n=31; human epidermal growth factor receptor 2 (HER2)-enriched: n=16; TNBC: n=32]. Among the 12 metabolic parameters from APTw imaging, only amide values of the malignant group were significantly higher than those of the benign group (P=0.002). Malignant lesions also exhibited lower ADC values and higher Ktrans and Kep values (P<0.05). The combination of amide, ADC, Ktrans, and Kep yielded an AUC of 0.932 [95% confidence interval (CI): 0.891-0.968]. For differentiating TNBC from non-TNBC, the CEST-derived parameter downfield nuclear Overhauser effect-suppressed apparent exchange-dependent relaxation (DNS-AREX) showed significant differences, achieving an AUC of 0.762 (95% CI: 0.665-0.842), with a sensitivity of 91.7% and a specificity of 68.5%. No significant differences were observed for DWI or DCE-MRI parameters between TNBC and non-TNBC. Conclusions: Multipool CEST provides complementary value to conventional MRI for breast lesion characterization. The CEST-derived parameter DNS-AREX demonstrated a modest but statistically significant ability to identify TNBC, while conventional DWI and DCE-MRI parameters did not exhibit significant predictive ability. APTw imaging may serve as a noninvasive imaging biomarker for molecular subtyping in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.